Skip to content
foodoseGet my numbers
ScienceJune 8, 20263 min read

A drug aimed at GLP-1's biggest flaw: keeping muscle while you lose fat

A combination of semaglutide and an experimental drug called bimagrumab reached 22% weight loss with almost all of it coming from fat: lean mass loss was held to under 3%, versus 7.4% on semaglutide alone.

What happened

For years the muscle question hung over GLP-1 drugs: a meaningful share of the weight people lose is not fat but lean mass, muscle and the tissue that holds you up. At the American Diabetes Association meeting, researchers showed one of the first serious attempts to fix it in a drug.

In the BELIEVE trial, bimagrumab (an experimental drug that builds muscle) was combined with semaglutide. The combination reached about 22% weight loss, and crucially, 92% of that loss came from fat. Lean-mass loss was held to under 3%, compared with 7.4% on semaglutide alone. People lost more total weight and kept more muscle.

Why this is the important number

This is the clearest sign yet that the field has accepted what the muscle research has said all along: how much you lose matters less than what kind of weight you lose. A scale that drops by taking muscle leaves you smaller but weaker, with a slower metabolism and a higher chance of regaining fat later.

The fact that drugmakers are now building medicines specifically to protect lean mass is, in a way, the strongest possible endorsement of treating muscle as the real outcome. It is no longer a niche concern. It is the next frontier.

The part you do not have to wait for

Here is what often gets lost: bimagrumab is years from your pharmacy, but the result it produces is something you can already protect yourself, today, on the drug you are on now.

The two proven tools cost nothing and work: enough protein (around 120g a day) and two short resistance-training sessions a week. In the research, together they cut muscle loss by 50 to 95%. That is not far off what an experimental muscle drug achieved. The women who do best on the next generation of these medicines are the ones already protecting their muscle on this one. (See why muscle is the number that matters.)

What it means for you

Read this as validation, not as something to wait for. The single idea behind this expensive new drug, lose fat without losing muscle, is the idea you can act on this week with protein and strength work.

What to do with this

A drug that protects muscle is years away. Protein and resistance work are available now, and the calculator sets the first of them from your adjusted body weight and your dose.

Set your protein floor

People also ask
Is there a drug that stops muscle loss on a GLP-1?
One is being tested. In the BELIEVE trial, presented at the 2026 American Diabetes Association meeting, an experimental muscle building drug called bimagrumab was combined with semaglutide. The combination reached about 22% weight loss, and 92% of that loss came from fat. Lean mass loss was held to under 3%, against 7.4% on semaglutide alone.
Why does the bimagrumab result matter?
Because it addresses the quiet cost of this drug class directly. A meaningful share of the weight people lose on a GLP-1 is not fat but lean mass, the muscle and tissue that holds you up. In BELIEVE people lost more total weight and kept more muscle, which is the combination that had not been shown before. That the drug industry is now chasing this goal tells you how real the problem is.
Read the originalADA 2026 / Nature MedicineOpen

From the recipe collection

Recipes that fit

Each with a stated portion and its nutrition calculated from the ingredients.

Go deeper

The news changes weekly. What protects your body doesn't.

Work yours out once: your calorie target, your protein floor, and three days of food built to them. Free, and no sign-up.

More from the Brief